First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small-cell lung cancer: A phase II randomized trial of Gruppo Oncologico Italia Meridionale
Vittorio Gebbia(Università degli Studi di Enna Kore), Giuseppe Colucci(Roche (Switzerland)), Domenico Galetta(Istituto Tumori Bari), Francesco Carrozza(Ospedale per gli Infermi), Evaristo Maiello(Casa Sollievo della Sofferenza), Francesco Ferraù(Université Paris-Sud), Michele Caruso(Humanitas Mater Domini), Nicolò Borsellino(Ospedale Buccheri la Ferla Fatebenefratelli), Silvana Leo(Ospedale Vito Fazzi), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Vito Lorusso(Ospedale Vito Fazzi), Saverio Cinieri(Ospedale A. Perrino)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743